Carrie Palmer, MD
Ophthalmology · Stuart, FLNPI 1144484106
Payments from drug & device makers
Across 116 payments — averaging $33.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$824
- Glaukos Corporation$546
- AbbVie$352
- Ocular Therapeutix, Inc.$262
- Novartis$242
- Sun Pharmaceutical Industries Inc.$214
- plus $1K from 21 others
What the payments were for
- Speaking & faculty fees$201%
- Food & beverage$3,90099%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 12 | $824 |
| Glaukos Corporation | 7 | $546 |
| AbbVie(2 entities) | 8 | $352 |
| Ocular Therapeutix, Inc. | 8 | $262 |
| Novartis | 11 | $242 |
| Sun Pharmaceutical Industries Inc. | 9 | $214 |
| Rxsight Inc | 7 | $210 |
| Mallinckrodt Hospital Products Inc. | 7 | $181 |
| Bausch & Lomb Americas Inc. | 7 | $135 |
| Omeros Corporation | 1 | $108 |
| Sight Sciences, Inc. | 5 | $97 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $95 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $89 |
| Tarsus Pharmaceuticals, Inc. | 3 | $73 |
| Amgen(2 entities) | 3 | $61 |
| Kala Pharmaceuticals, Inc. | 3 | $61 |
| Oyster Point Pharma, Inc. | 3 | $60 |
| Harrow Eye, LLC | 2 | $57 |
| Dompe US, Inc. | 2 | $54 |
| Rayner Intraocular Lenses Limited | 2 | $51 |
| Eyepoint US, Inc. | 2 | $33 |
| ANI Pharmaceuticals, Inc. | 1 | $26 |
| Eyevance Pharmaceuticals LLC | 1 | $22 |
| Aerie Pharmaceuticals, Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $18 |
| Biotissue Holdings Inc. | 1 | $14 |
| NEW World Medical,inc. | 2 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Photrexa Viscous and Photrexa$315
- LenSx$243
- Clareon$141
- Centurion$127
- DEXTENZA$124
- iStent Trabecular Micro-Bypass System Model iS3$123
- Clareon PanOptix Pro$123
- VUITY$123
- DURYSTA$115
- OMIDRIA$108
How this compares
$3,920 in reported general payments places this provider in the 65th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 170 | $117,000 |
| XiidraLifitegrast | 17 | $17,227 |
| Cyclosporine | 38 | $17,110 |
| VyzultaLatanoprostene Bunod | 30 | $14,598 |
| LumiganBimatoprost | 22 | $11,485 |
| RhopressaNetarsudil Mesylate | 20 | $11,066 |
| Prednisolone Acetate | 234 | $8,746 |
| CombiganBrimonidine Tartrate/Timolol | 19 | $5,361 |
| Timolol Maleate | 110 | $4,089 |
| Loteprednol Etabonate | 22 | $3,420 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 12 | $3,283 |
| TobradexTobramycin/Dexamethasone | 12 | $3,140 |
| Latanoprost | 291 | $3,000 |
| Brimonidine Tartrate | 165 | $2,906 |
| MoxifloxacinMoxifloxacin Hcl | 81 | $2,725 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $352 | $133,846211 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $135 | $31,82547 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $22 | $11,06620 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $89 | $3,42022 claims |
| AlconSimbrinza | $824 | $3,28312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Stuart
- Ronald FrenkelStuart$2.1M
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.